Ha habido 50 transacciones internas recientes registradas para Calithera Biosciences, Inc. (CALA), incluyendo 25 compras y 25 ventas. El total de compras internas fue valorado en $1.11M y el total de ventas internas en $80.46M.
Internos destacados con actividad reciente incluyen Takeda Pharmaceutical Co Ltd, Pakianathan Deepika, Molineaux Susan. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — CALA
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2023-04-17 |
Takeda Pharmaceutical Co Ltd |
Officer |
Otro (Venta) |
1,000,000 |
$40.08 |
$40.08M |
- |
| 2023-01-27 |
Pakianathan Deepika |
Director |
Venta Informativa |
1,172 |
$0.39 |
$452.16 |
- |
| 2023-01-23 |
Molineaux Susan |
President & CEO |
Retención Fiscal de RSU |
526 |
$0.45 |
$234.65 |
27,859 |
| 2023-01-23 |
Wong Stephanie |
See Remarks |
Retención Fiscal de RSU |
317 |
$0.45 |
$141.41 |
6,287 |
| 2023-01-23 |
Sjogren Eric |
Sr. VP, Drug Discovery |
Retención Fiscal de RSU |
279 |
$0.45 |
$124.46 |
8,467 |
| 2023-01-23 |
Molineaux Christopher |
Sr. VP, Development |
Retención Fiscal de RSU |
217 |
$0.45 |
$96.80 |
27,859 |
| 2023-01-23 |
Kuriakose Emil |
Chief Medical Officer |
Retención Fiscal de RSU |
79 |
$0.45 |
$35.24 |
3,539 |
| 2022-07-01 |
Takeda Pharmaceutical Co Ltd |
10 Percent Owner |
Otro (Venta) |
1,000,000 |
$40.08 |
$40.08M |
- |
| 2022-07-01 |
Takeda Ventures, Inc. |
Director |
Otro (Venta) |
1,000,000 |
- |
- |
- |
| 2022-06-01 |
Pakianathan Deepika |
Director |
Concesión de RSU |
20,000 |
- |
- |
20,000 |
| 2022-06-01 |
Wolff Henry Ward |
Director |
Concesión de RSU |
20,000 |
- |
- |
20,000 |
| 2022-06-01 |
Garland J. Scott |
Director |
Concesión de RSU |
20,000 |
- |
- |
20,000 |
| 2022-06-01 |
Agarwal Sunil |
Director |
Concesión de RSU |
20,000 |
- |
- |
20,000 |
| 2022-06-01 |
Wise Blake |
Director |
Concesión de RSU |
20,000 |
$0.20 |
$4K |
20,000 |
| 2022-06-01 |
Orford Keith |
Director |
Concesión de RSU |
20,000 |
$0.20 |
$4K |
20,000 |
| 2022-06-01 |
Jones Suzy |
Director |
Concesión de RSU |
20,000 |
- |
- |
20,000 |
| 2022-01-25 |
Molineaux Susan |
President & CEO |
Concesión de RSU |
597,475 |
$0.44 |
$262.89K |
597,475 |
| 2022-01-25 |
Wong Stephanie |
See Remarks |
Concesión de RSU |
215,000 |
$0.44 |
$94.6K |
215,000 |
| 2022-01-25 |
Ray Sumita |
See Remarks |
Concesión de RSU |
165,000 |
$0.44 |
$72.6K |
165,000 |
| 2022-01-25 |
Sjogren Eric |
Sr. VP, Drug Discovery |
Concesión de RSU |
165,000 |
$0.44 |
$72.6K |
165,000 |
| 2022-01-25 |
Molineaux Christopher |
Sr. VP, Development |
Concesión de RSU |
165,000 |
$0.44 |
$72.6K |
165,000 |
| 2022-01-25 |
Orford Keith |
Director |
Concesión de RSU |
40,000 |
$0.44 |
$17.6K |
40,000 |
| 2022-01-25 |
Parlati Francesco |
Sr. VP, Research |
Concesión de RSU |
165,000 |
$0.44 |
$72.6K |
165,000 |
| 2022-01-25 |
Kuriakose Emil |
Chief Medical Officer |
Concesión de RSU |
215,000 |
$0.44 |
$94.6K |
215,000 |
| 2022-01-21 |
Wong Stephanie |
See Remarks |
Retención Fiscal de RSU |
5,586 |
$0.49 |
$2.75K |
132,085 |
| 2022-01-21 |
Sjogren Eric |
Sr. VP, Drug Discovery |
Retención Fiscal de RSU |
4,794 |
$0.49 |
$2.36K |
172,434 |
| 2022-01-21 |
Parlati Francesco |
Sr. VP, Research |
Retención Fiscal de RSU |
4,794 |
$0.49 |
$2.36K |
140,998 |
| 2022-01-21 |
Kuriakose Emil |
Chief Medical Officer |
Retención Fiscal de RSU |
666 |
$0.49 |
$327.34 |
67,369 |
| 2022-01-04 |
Wong Stephanie |
See Remarks |
Retención Fiscal de RSU |
18,077 |
$0.66 |
$11.94K |
137,671 |
| 2022-01-04 |
Sjogren Eric |
Sr. VP, Drug Discovery |
Retención Fiscal de RSU |
18,077 |
$0.66 |
$11.94K |
177,228 |
| 2022-01-04 |
Parlati Francesco |
Sr. VP, Research |
Retención Fiscal de RSU |
18,077 |
$0.66 |
$11.94K |
145,792 |
| 2022-01-04 |
Kuriakose Emil |
Chief Medical Officer |
Retención Fiscal de RSU |
3,855 |
$0.66 |
$2.55K |
68,035 |
| 2021-11-11 |
Orford Keith |
Director |
Venta Informativa |
48,190 |
$0.88 |
$42.41K |
66,094 |
| 2021-11-10 |
Molineaux Susan |
President & CEO |
Compra Informativa |
100,000 |
$0.85 |
$84.67K |
557,188 |
| 2021-11-10 |
Drachman Jonathan G |
Director |
Compra Informativa |
200,000 |
$0.86 |
$171.9K |
200,000 |
| 2021-11-10 |
Molineaux Christopher |
Sr. VP, Development |
Compra Informativa |
100,000 |
$0.85 |
$84.67K |
557,188 |
| 2021-11-10 |
Orford Keith |
Director |
Venta Informativa |
30,000 |
$0.86 |
$25.7K |
114,284 |
| 2021-11-09 |
Orford Keith |
Director |
Venta Informativa |
51,810 |
$0.84 |
$43.52K |
144,284 |
| 2021-11-08 |
Wong Stephanie |
See Remarks |
Retención Fiscal de RSU |
15,566 |
$0.87 |
$13.54K |
155,748 |
| 2021-11-08 |
Sjogren Eric |
Sr. VP, Drug Discovery |
Retención Fiscal de RSU |
15,566 |
$0.87 |
$13.54K |
195,305 |
| 2021-11-08 |
Parlati Francesco |
Sr. VP, Research |
Retención Fiscal de RSU |
15,566 |
$0.87 |
$13.54K |
163,869 |
| 2021-11-08 |
Kuriakose Emil |
Chief Medical Officer |
Retención Fiscal de RSU |
3,077 |
$0.87 |
$2.68K |
69,390 |
| 2021-11-05 |
Wong Stephanie |
See Remarks |
Concesión de RSU |
30,000 |
- |
- |
171,314 |
| 2021-11-05 |
Ray Sumita |
See Remarks |
Concesión de RSU |
12,000 |
- |
- |
105,000 |
| 2021-11-05 |
Sjogren Eric |
Sr. VP, Drug Discovery |
Concesión de RSU |
30,000 |
- |
- |
210,871 |
| 2021-11-05 |
Molineaux Christopher |
Sr. VP, Development |
Concesión de RSU |
12,000 |
- |
- |
102,500 |
| 2021-11-05 |
Orford Keith |
Director |
Concesión de RSU |
30,000 |
- |
- |
196,094 |
| 2021-11-05 |
Parlati Francesco |
Sr. VP, Research |
Concesión de RSU |
30,000 |
- |
- |
179,435 |
| 2021-11-05 |
Kuriakose Emil |
Chief Medical Officer |
Disposición |
33,375 |
$2.98 |
$99.46K |
- |
| 2021-11-05 |
Kuriakose Emil |
Chief Medical Officer |
Concesión de RSU |
12,000 |
- |
- |
72,467 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento